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ABSTRACT 
INTRODUCTION 
 Many patients present to the surgical department with a thyroid 
nodule. However not all require surgery and only 5-6% of these are 
malignant. There are many methods to diagnose and predict malignancy 
in thyroid nodules. This study throws light on the usefulness of 
combining clinical, radiological and laboratory investigations into a 
single scoring system which is used to predict the risk of malignancy in 
thyroid nodules thereby helping the surgeon to make appropriate 
decisions regarding the operative management and follow up of the 
patient. 
AIMS AND OBJECTIVES 
 To evaluate a scoring system using clinical, laboratory and 
sonological data for predicting the risk of malignancy in patients with 
thyroid nodules, in a tertiary care centre in South India, which caters 
mostly for an economically underprivileged population. 
MATERIALS AND METHODS 
 This prospective observational study involved 50 patients admitted 
in MMC, Chennai with thyroid nodules. Analysis of a scoring system was 
done which combined clinical findings, radiological features and 
laboratory findings such as TSH level and FNAC report. The final scores 
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were compared with the post-operative histopathology of the patient and 
the risk of malignancy was predicted.  
OBSERVATION AND RESULTS 
 The scoring system had a maximum score of 26. The observed 
score ranged from 3 to 19. The mean score was 11. All the malignant 
cases observed in our study had a score greater than 11. The incidence of 
thyroid carcinoma for scores of 1 to 11 was 0%, 12 to 13 was 20%, 14 to 
18 was 75% and ≥19 was 100%. The average risk of malignancy for a 
score ≤11 was 0% and for a score >11 was 54.166%.The sensitivity and 
specificity of the scoring system was 70.2% and 100% respectively.The 
positive and negative predictive value for the scoring system was 100% 
and 43.83% respectively.The greater risk of malignancy demonstrated for 
patients above a score of 11 was statistically significant (p<0.0001, χ2 = 
14.965, df = 1). The risk of malignancy increased with increasing scores 
and was found to be 100% for a score ≥16. 
 
CONCLUSION 
 This scoring system has proved to be accurate in predicting the risk 
of malignancy in patients with thyroid nodules by combining various 
parameters derived from the patient’s history, clinical examination and 
simple, cost-effective investigations like thyroid function test, 
ultrasonogram and FNAC. Each of these factors has variable reliability, 
3 
but their combination has proven to be a better predictor of malignancy. It 
can be routinely introduced in every hospital for pre-operative assessment 
of patients presenting with thyroid nodules, thus helping the surgeon to 
make rational and individualized decision while treating such patients. 
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INTRODUCTION 
 
1. BACKGROUND 
 
              The incidence of thyroid nodules is on the rise and so is the 
incidence of thyroid malignancy. One of the greatest challenges for a 
clinician is the evaluation and follow-up of patients presenting with 
thyroid nodules. It is essential to identify the patients harboring a 
malignant disease and those having a benign lesion. 
             Several clinical characteristics, laboratory investigations and 
imaging modalities have been associated with the risk of malignancy in 
thyroid nodules[1]. These data have been integrated into various scoring 
systems. An ideal scoring system would reduce the need for costly 
imaging and unwanted exposure and at the same time increase the 
precision of decision making.  
             In our study we have put together a scoring system using clinical, 
laboratory and radiological data for evaluating the risk of malignancy in 
thyroid nodules. These risk factors have been analyzed in various other 
studies and found to have specific predictive value for malignancy[2]. The 
aim of our study is to evaluate this scoring system for predicting the risk 
of malignancy. 
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2. OBJECTIVES 
1. To evaluate a scoring system for predicting the risk of malignancy 
in thyroid nodules using clinical, laboratory and sonological data. 
2. To study the risk factors having high predictive value.       
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2.1 HISTORY[3,4,5] 
 
The history of thyroid diseases can be traced back to ancient times. 
Celsus and Galen described goiters ( Latin: guttur = throat ) in 1st 
century A.D. 
Thomas Wharton (1656) coined the term thyroid gland   (Greek 
:thyreoeides = shield ) because of its appearance like a shield protecting 
the trachea. 
Andrea Vesalius (1514 – 1564) coined the term 
“glandulaelaryngis ” in his book De HumaniCorporisFabrica. 
 Lorenz Heister of Germany first described the surgery for removal 
of a thyroid. 
 AnitonWolflerwas the first surgeon to describe the recurrent 
laryngeal nerve during thyroidectomy. 
 Theodor Billroth (1892 – 1894) and Theodor Kocher (1849 – 
1917) were eminent surgeons who performed thyroid surgeries in the 19th 
century. Kocher became a Nobel laureate in 1909, being recognized for 
his work. 
 IvarSandstrom (1887) of Sweden discovered parathyroids and 
described their anatomy and blood supply. 
 C. H.Mayo of USA had tremendous experience in thyroid surgery. 
Reports from the Mayo clinic had been an important factor in 
9 
disseminating anunderstanding of the surgical technique and operative 
difficulties, which, in turn, greatly improved thyroid surgery. 
 William Halstead (1852 – 1922) of USA stressed the importance 
of preservation of parathyroids during thyroid surgery. 
 Martin and Ellis (1930) first described FNAC of thyroid. 
 Duffy et al (1950) studied relationship of papillary carcinoma of 
thyroid and neck irradiation in childhood. 
 Hazard et al, in 1950, discovered medullary carcinoma of thyroid. 
 Sipple(1960) observed that medullary carcinoma of thyroid was 
associated with pheochromocytoma. 
 Development in molecular medicine in the 1980s has provided 
major insight into the impact of genetic mutations leading eventually to 
thyroid carcinomas. This lead to the introduction of different surgical 
strategies. 
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2.2 ANATOMY OF THYROID GLAND[6] 
 
 The thyroid gland is butterfly shaped wit two lateral lobes, an 
isthmus, and occasionally a pyramidal lobe. it is brownish in color. On 
palpation, it is firm in consistency. It is located posterior to the strap 
muscles of the neck.10 percent of population may not have the 
isthumusand the pyramidal lobe is present only in 50 percent. The thyroid 
gland normally extends from C5 to T1 vertebra.  
 
 
Fig 1: Anatomy of thyroid gland 
The normal thyroid gland weighs about 30 g in the adult. The 
dimension of each lobe is about 5x3x2 cm. The isthmus connecting the 
11 
two lobes is about 1.3 cm in breadth. The lobes have a broad lower 
portion and a relatively conical apex. 
 
CAPSULE OF THE THYROID GLAND 
The true capsule of the thyroid, continues with the septa, and 
makes up the stroma of the gland.  
The false capsule lies outside the true capsule and is a derivative 
of the pre-tracheal layer of deep cervical fascia. It is thick anteriorly and 
laterally; posteriorly it becomes thinned out, allowing the gland to expand 
posteriorly. The false capsule is retained with the gland during 
thyroidectomy. The ligaments of Berry are thickened portions of the pre-
tracheal fascia, which attach the gland to the cricoid cartilage. 
 
PARATHYROID GLANDS 
Normal parathyroid glands weigh 30 to 50 mg and are 
approximately the size of a grain of rice (3 to 5 mm). The color, texture, 
and appearance of parathyroid glands vary considerably, ranging from 
golden to reddish brown and becoming a more pale yellow as the fat 
content increases.  
The superior parathyroid glands are normally situated on the 
postero-medial surface of middle to superior thyroid lobe, near the 
trachea-esophageal groove. They reside under the superficial fascia of the 
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thyroid, posterior to the recurrent laryngeal nerve (RLN). When a 
tubercle of Zuckerkandl of the thyroid lobe is present, these glands are 
often found posteromedial to the tubercle. They are found between the 
two capsules. 
Inferior parathyroid glands usually lie just under the lower part 
ofthyroid lobe and anterior to RLN. They may be between the two 
capsules or within thesubstance of the gland or on the surface of the false 
capsule. 
 
VASCULAR SUPPLY 
 The thyroid gland is supplied by the external carotid system via the 
superior thyroid artery and the subclavian system via the inferior thyroid 
artery. Sometimes there may be an additional artery, the thyroid ima 
artery arising from the brachiocephalic artery. 
 
SUPERIOR THYROID ARTERY 
The superior thyroid artery is a branch of the external carotid 
artery. It reaches the superior pole of the gland by passing downwards 
and laterally. The artery runs close to the external laryngeal nerve in a 
part of its course. At the superior pole of the gland, it divides into an 
anterior and a posterior branch. The superior parathyroid gland is 
supplied by the posterior branch. 
13 
 
Fig 2: Blood supply of thyroid gland 
 
INFERIOR THYROID ARTERY 
It originates from thyro-cervical trunk. In about 15% of cases, it 
arises directly from the sub-clavian artery. It pierces the pre-vertebral 
fascia and splits into 2 or more branches as it crosses the RLN. The 
recurrent laryngeal nerve has variable relations to the branches of the 
artery. One of the lower branches of the artery supplies the inferior 
parathyroid. The posterior part of the gland is supplied by the upper 
branch which ends by joining the descending branch of superior thyroid 
artery. 
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THYROID-IMA ARTERY 
The thyroid-ima artery originates from the brachiocephalic artery 
or directly the aortic arch. It occurs in about 10 percent of individuals, 
according to Montgomery.  
 
VENOUS DRAINAGE 
Three pairs of veins - the superior, middle and inferior thyroid 
veins, drain the thyroid gland. 
 
SUPERIOR THYROID VEIN 
It emerges from the upper pole of the thyroid, passes across the 
common carotid artery and omo-hyoid muscle and enters the internal 
jugular vein.  
 
Fig 3: Venous drainage of thyroid gland 
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MIDDLE THYROID VEIN 
The middle thyroid vein arises on the lateral surface of the gland. It 
does not have an accompanying artery. It travels across the common 
carotid artery and opens into the internal jugular vein.  
 
INFERIOR THYROID VEIN 
It is the largest vein arising from the thyroid.It drains into the 
brachiocephalic vein. The thyroid-ima vein is a common trunk formed 
occasionally by the union of right and left veins. 
 
FOURTH THYROID VEIN OF KOCHER 
 It may emerge between the middle and the inferior thyroid veins 
and drains into the internal jugular vein.  
 
LYMPHATIC DRAINAGE 
The thyroid gland has an extensive supply of lymphatics. The 
lymphatic drainage can be divided into four zones (Hollinshead). 
 
1. MEDIASTINAL SUPERIOR DRAINAGE 
From the upper part of the isthumus and the inner margins of the 
lobes. Drains primarily into the digastric lymph nodes and into the pre-
laryngeal (Delphian) nodes just above the isthumus. Secondarily it may 
drain into the upper jugular nodes or into pre-tracheal. 
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2. MEDIAN INFERIOR DRAINAGE 
 Lymphatics draining the inferior part of the isthumus and the 
infero-medial portions of the lobes. They drain into the pre-tracheal and 
brachiocephalic nodes. 
 
 
Fig 4: Lymph node levels in the neck 
3. RIGHT AND LEFT LATERAL DRAINAGE 
 Superiorly follow superior thyroid artery and vein. Inferiorly they 
follow the inferior thyroid artery. 
4. POSTERIOR DRAINAGE 
 Drains into the retropharyngeal nodes. 
 The thyroid lymphatics drain first into the level-VI nodes (central 
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compartment) containing the pre-tracheal and para-tracheal nodes and 
subsequently into the level II-IV nodes (lateral jugular).  
 
NERVE SUPPLY 
 The thyroid gland is supplied by the sympathetic system from the 
cervical chain. But in thyroid surgery the recurrent and superior laryngeal 
nerves of the parasympathetic (vagus) system are of utmost importance. 
 
EXTERNAL LARYNGEAL NERVE 
It is a branch of the Superior Laryngeal Nerve of Vagus. It passes 
deep to the sternothyroid, posterior and medial to the superior thyroid 
vessels. The nerve innervates the cricothyroid muscle. Cernea et al. stated 
that injury to this nerve would most likely cause a permanent voice 
change for professional vocalists. Fatigue, also, is common after injury 
 
Fig 5: Nerve supply of thyroid gland 
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RECURRENT LARYNGEAL NERVE 
 It is intimately related to the thyroid gland. They innervate all the 
intrinsic laryngeal muscles except cricothyroid. On the right side, it arises 
from the vagus as it crosses the right sub-clavian arteryand hooks around 
the subclavian artery and ascends in the trachea-esophageal groove. It 
courses behind the right lobe and enters the larynx behind the 
cricothyroid articulation. 
The left recurrent nerve arises where the vagus nerve crosses the 
aortic arch. It winds around the ligamentum-arteriosum and aorta, and 
ascends similar to the right nerve. It is related to the inferior thyroid 
artery near the middle-third of the gland.  
Exposing the nerve during surgery is a goodpractice. The nerve can 
be recognized where it enters the larynx just behind the inferior-cornu of 
the thyroid cartilage. If not found, a non-recurrent nerve ought to be 
looked for, particularly on the right. Pelizzo et al. advised that the best 
way to locate the recurrent laryngeal nerve during thyroidectomy is the 
Zuckerkandl'stuberculum, which is located on the lateral portion of each 
of the thyroid lobes. It is the posterior-most portion of the lateral lobes at 
the level of the Berry’s ligament.  
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EMBRYOLOGY[7] 
An epithelial proliferation arises in the floor of the tongue at the 
foramen caecum which gives rise to the thyroid gland.Subsequently it 
descends as a bilobed diverticulum in front of the pharynx. The 
attachment to the tongue forms the thyroglossal duct. This duct usually 
vanishes by the 6th week. The gland descends in front of the hyoid bone, 
and reaches its final stationby the 7th week. The gland develops two 
lateral lobes connected by the isthmus.It starts functioning by the 3rd 
month. The cells of the ultimo-branchial body becomethe C (calcitonin) 
cells among the thyroid follicles. 
 
HISTOLOGY[6,7] 
The thyroid capsule is a slender layer of connective tissue. From 
the capsule, several septa extend within the thyroid parenchyma, which is 
subdivided into several lobules. Epithelial cells (cuboidal or squamous) 
form the thyroid follicles; they are separated by thin connective stroma, 
which is rich in both lymphatic and blood vessels. There is a colloidal 
gelatinous collection in the center of the follicle. Each follicle has two 
types of cells: follicular and parafollicular cells, or C cells. 
20 
 
Fig 6: Histology of thyroid follicle 
 
The follicular cells are responsible for the following actions: 
synthesis of thyroglobulin, iodination, storage of thyroglobulin, 
resorption of thyroglobulin, hydrolysis of thyroglobulin, and release of 
thyroid hormone into the blood and lymphatics. The parafollicular, or C 
cells, can be found in the connective stroma between the follicles or in the 
follicular epithelium. Characteristically, they contain several secretory 
granules. 
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2.3 PHYSIOLOGY OF THYROID GLAND[8,9] 
 
The normal thyroid gland secretes three hormones – 
triiodothyronine (T3) and tetraiodothyronine (T4) from the follicular cells 
to normalize growth and development, body temperature and energy 
levels. Calcitonin the third hormone is produced by parafollicular cells 
and regulates calcium metabolism.  
 
THYROID HORMONE SYNTHESIS 
 Iodine in diet is converted to iodides which are utilized by the 
thyroid gland to synthesize thyroid hormones. Thyroglobulin (Tg) is a 
glycoprotein manufactured in the thyroid cells. By exocytosis, it is 
secreted into the colloid.  
 
STEPS 
1. IODIDE TRAPPING 
 Iodide is actively transported across the basement membrane of the 
thyrocyte in an ATP dependent manner. 
 
2. OXIDATION 
 Iodide is oxidizedinto iodine. The tyrosine residues on 
thyroglobulin become iodinated to form monoiodotyrosines (MIT) and 
diiodotyrosines (DIT). This step is catalyzed by thyroid peroxidase 
(TPO). 
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3. COUPLING 
  2 DIT molecules combine to form tetra-iodothyronine or thyroxine 
(T4). A DIT molecule joins with an MIT molecule to form 3,5,3’-triiodo-
thyronine (T3) or 3,3’,5’- triiodo-thyronine reverse (rT3).  
 
4.HYDROLYSIS 
 Thyroglobulin undergoes hydrolytic breakdownto release free T3, 
T4,mono and di iodotyrosines. 
 
THYROID HORMONE RELEASE AND TRANSPORT 
 In the euthyroid state, the thyroid gland produces most of T4 but 
only 20% of the total T3. Most of the T3 is produced by peripheral 
deiodination of T4 by 5’-mono-deiodinase. Some amount of T4 
undergoes deiodination of inner ring to form rT3.  
 The hormones are carried in serum bound with proteins like T4-
binding globulin, T4-binding pre-albumin and albumin.Only 0.02% is 
unbound and is the physiologically active form. T3 is more potent of the 
two thyroid hormones, although its circulating plasma level is much 
lower than that of T4. T3 is less tightly bound to plasma proteins than T4 
so it enters tissues easily. It is three to four times more active than T4 per 
unit weight, with a half-life of one day compared to approximately seven 
days for T4. 
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REGULATION OF THYROID HORMONES 
 The hypothalamic – pituitary-thyroid axis controls the secretion of 
hormones. The hypothalamus produces the thyrotropin-releasing-
hormone(TRH). This in turnexcites the pituitary to discharge TSH or 
thyrotropin. TRH is transported to the pituitary by the porto-venous 
circulation. 
 
THYROID STIMULATING HORMONE (TSH) 
It is a glycoprotein containing 211 aminoacids. It is secreted in a 
pulsatile manner from the anterior-pituitary gland. There are two 
subunits: the α-subunit is similarto the rest of the anterior-pituitary 
hormones; the β-subunit is exceptional to TSH. Once TSH binds to the 
receptor (TSH-R) on thyroid cells, it interacts with a ‘G-protein’, which 
in turn stimulates the synthesis of cyclic-adenosine-monophosphate 
(cAMP). This is thekeyhormone synthesizing pathway. The biological 
half-life of human TSH is about 60 minutes. It is degraded mostly in the 
kidneys and to a certain extent in the liver. The normal secretion rate is 
about 110 microgram/day. The average plasma level is 2 microgram/mL. 
 
TSH secretion is regulated by a negative feedback loop. Its 
secretion is augmented by TRH and repressed by circulating fT4 and fT3 
by a negative-feedback mechanism. Stress also inhibits TSH secretion. In 
experimental animals, it is decreased by warmth and increased by cold.  
24 
 
 
Fig 7: Regulation of thyroid hormones 
 
  
Excessively large doses of iodide cause increased organification 
and termination of production. This is known as Wolf–Chaikoff effect. 
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2.4 THYROID MALIGNANCIES[6,10,11] 
  
Among the endocrine malignancies, thyroid malignancies are the 
commonest. They account for 94.5% of total new cases and 66% of all 
endocrine carcinoma related deaths. Majority of thyroid cancers present 
as nodules.  The risk of development of malignancy in each thyroid 
nodule is 5-10% in the total population. The risk is higher for males and 
in the extremes of age. There is a 33-37% chance of malignancy in 
patients with history of childhood neck irradiation. A solitary-nodule has 
greater risk of malignancy (15-25%) than a multinodular goiter (1-6%). A 
history of rapid increase in size, breathlessness, difficulty in swallowing, 
hoarseness of voice is highly suspicious of malignancy.  
 
CLASSIFICATION OF THYROID MALIGNANCIES 
PRIMARY 
1. Arising from the follicular epithelium 
 a. Well differentiated (90%) – Papillary, Follicular 
 b. Undifferentiated (1-2%) – Anaplastic 
2. Arising from parafollicular cells (5-9%) – Medullary 
3. Arising from lymphoid cells (1-3%) – Lymphoma 
4. Arising from stromal cells (1%) – sarcomas 
SECONDARY 
Metastatic 
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ETIOLOGY OF THYROID MALIGNANCY 
RADIATION EXPOSURE 
Exposure to radiation is asignificant risk factor for development of 
well-differentiated thyroid tumors. The younger the age at exposure, the 
greater is the risk. The risk is proportional to the exposure dose 
(minimum dose of 10cGy). Latent period after childhood exposure is 3-5 
years. Majority of cases develop between the second and third decade. 
 
SEX 
 Well-differentiated carcinomas are around two and a half times 
more common in women. The median age at which it is diagnosedis also 
earlier in females than in males. 
 
FAMILY HISTORY 
 There is a four to ten fold amplified risk of differentiated tumors in 
1st degree relations. 
 
DIET 
 Iodine deficient diets lead to elevated TSH and may begoitrogenic. 
Excessive iodine consumption in seafood is associated with a higher 
incidence of papillary carcinoma. 
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THYROID ONCOGENESIS[11] 
 Numerous tumor suppressor genes and oncogenes are implicated in 
thyroid oncogenesis. One of them is the RET proto-oncogene 
(chromosome 10) which codes a receptor - tyrosinekinase that binds 
several growthfactors. Germ-line mutations in the RET protooncogene 
predisposes to MEN2A, MEN2B and familial medullary thyroid cancers. 
The tyrosinekinase of RET fuses with other genes by re-arrangement. 
These products function as oncogenes and have been incriminated in the 
genesis of papillary cancer. BRAF mutations have been identified in40%  
papillary carcinomas. Mutated RAS oncogenes have been recognized in 
upto 40% of follicular adenomas/carcinomas, papillary and anaplastic 
cancers. Mutation of p53 tumor suppressor gene is common in 
undifferentiated thyroid carcinomas and carcinoma cell lines. The 
oncogene resulting from the union of the DNA-binding domain of 
transcription factor PAX8 gene with the PeroxisomeProliferator-
Activated Receptor Gamma 1 (PPAR-y1) is known to play avital role in 
the oncogenesis of follicular cancer. 
 
  
This carcinoma accounts for eighty to eighty
malignant thyroid carcinomas
1. solitary painless nodule thyroid
2. solitary nodule with lymph node metastasis
3. lymph node metastasis with occult primary 
thyroid 
Fig 8: patient presenting with thyroid nodule
PATHOLOGY 
 It is the common
exposed to ionizing
patients usually present at thirty to forty 
painless mass in the neck
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lymphnodes is very usual (80%) and may be one of the initial presenting 
features. 
On gross examination, it is hard and appears whitish on cut-
section. Histologically, they reveal papillary structures, mixed papillary 
with follicular pattern, or a purely follicular pattern (Follicular Variant). 
They contain cuboidal cells with abundant pale cytoplasm andclosely 
packed nuclei demonstrating “grooving”. There are intra-nuclear 
cytoplasmic inclusions calledOrphan Annienuclei which is characteristic. 
Psammoma bodies, which are clumps of calcified sloughedcells are also 
present. Multifocality is common in papillary carcinoma. 
Minimal/occult or microcarcinoma are tumor ≤1 cm in dimension, 
without localinvasion or lymphatic metastases.  
FOLLICULAR CARCINOMA 
They comprise ten percent of thyroid carcinomas. They 
occurfrequently in iodine-insufficient regions. It can present as 
1. solitary nodule 
2. MNG  
3. Distant metastasis 
 The female to male ratio is 3:1. They usually present at 50 years of 
age.Unlike papillary carcinomas, lymphnode metastasis occurs in 5% 
cases, whereas blood-borne metastasis occurs in 90% of cases. FNAC 
cannot distinguish benign follicular lesions from follicular carcinomas. 
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PATHOLOGY 
Follicular carcinomas are capsulated. Microscopically, it contains 
follicles,but the lumen may not contain colloid. Malignancy can be 
identified by the occurrence of capsular or vascular invasion. Minimally 
invasive carcinomas are encapsulated but have microscopic penetration 
into the capsule without invasion in to parenchyma. Tumors that are 
widely invasive, show penetration of large vessels or tumor capsule. In 
contrast to papillary carcinoma, follicular carcinoma is unifocal in origin. 
HURTLE CELL CARCINOMA 
They account for 3% of all thyroid malignancies. Theyare 
considered a variation of follicular carcinoma. FNAC cannot be used for 
diagnosing Hurthle cell carcinoma as they are characterized by capsular 
and vascular invasion. They contain areas of eosinophilic cells which are 
laden with mitochondria derived from oxyphilic cells. They are more 
often multifocal.30% of tumors are bilateral. They usually do not take up 
RAI. Twenty-five percentage of them metastasize to local nodes. They 
have a higher mortalityrate of about twenty percent at ten years. 
Treatment includes a total thyroidectomy with neck dissection. It is radio 
resistant. 
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MEDULLARY CARCINOMA 
Parafollicular“C-cells” are the cells of origin. It has an incidence of 
3-12% of thyroid cancers. There are two types of MTC namely sporadic 
form (60-70%) and familial form (30%). There are three distinct 
syndromes associated with familial MTC – MEN 2A, MEN 2B and 
Familial non-MEN MTC. These syndromes occur due to germ-line 
mutations in RET proto-oncogene. 
PATHOLOGY 
Sporadic disease is usually associated with unilateral presentation. 
Multicentricity is found in familial disease. Ninety percent of familial 
patients have a bilateral presentation. Familial disease is also linked with 
“C-cell hyperplasia”, a pre-malignant lesion.  
Histologically, the presence of amyloid is a diagnostic feature, but 
immunohistochemical staining for calcitonin isuniversally considered a 
diagnostic tumormarker.  
The age of presentation is usually fifty to sixty years. Familial 
cases present at anearlier age.The usual presentation is a thyroid mass 
associated with palpable cervical lymph nodes (15-20%). Pain is more 
common in this tumor and local invasion may produce symptoms of 
compression of adjacent structures. Distant blood-borne metastasis to the 
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liver, bone and lung occurs later. Patients with extensive metastatic 
disease often develop paraneoplastic symptoms like diarrhea and about 2-
4% of patients develop Cushing’s syndrome due to ectopic production of 
ACTH. 
TREATMENT 
If it is associated with pheochromocytoma, this has to be operated 
first. The surgery of choice for patients with MTC is total thyroidectomy. 
A prophylactic bilateral level-V nodal dissection must be routinely done 
as the central group of nodes are involved early in the disease. If the 
central or lateral group of nodes are palpable, then a Modified Radical 
Neck Dissection is done. Patients havingunresectable residual tumor or 
recurrent tumor can be treated with externalbeam radiotherapy. 
Chemotherapy is not very effective. 
ANAPLASTIC CARCINOMA 
It is a lethal malignancy with the worst prognosis of all thyroid 
malignancies. The patients usually survive only for four to five months 
after diagnosis. The mean age of diagnosis is the sixth and seventh 
decade with male to female ratio of 1:1.5. It usually develops due to de-
differentiation of prior well differentiated carcinoma. Other organs of 
metastasis include bone and liver. 
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Microscopy shows cells with striking cytological atypia. The 
mitotic activity of the cells is high. Necrosis of tumor and vascular 
invasion isusual. 33% of cases show coexisting areas of well-
differentiated cancer. 
CLINICAL FEATURES 
A rapidly growing neck mass is the usual presentation. Infiltration 
into the adjacent vital structuresis often present at diagnosis. Death occurs 
mainly due to loco-regional invasion leading to airway compromise. 
TREATMENT 
Survival after diagnosis is very poor. Radiotherapy has limited 
success. It is used to treat locally recurrent tumor. The most effective 
chemotherapeutic agent is doxorubicin.Doxorubicin with platinum is 
more efficient than monotherapy with doxorubicin alone. 
THYROID LYMPHOMA 
Thyroid lymphoma is rare constituting <1% of all lymphomas. 
Majority are non-Hodgkin’s lymphoma of intermediate grade. Many are 
thought to be Mucosa Associated Lymphoid Tissue-omas (maltomas) 
showingplasmacytic differentiation. Most of the cases have cervical or 
mediastinal lymph nodes at presentation. Thyroid lymphomas have a 
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strong preponderance for females with a female to male ratio of 8:1. They 
present between the 6th and 7th decade of life. Symptoms include 
hoarseness, breathlessness with stridor or difficulty in swallowing. 
Patients may be hypothyroid with Hashimoto’s thyroiditis. Treatment 
includes combination of surgery, EBRT and chemotherapy according to 
the histo-pathological type. 
METASTATIC CARCINOMA TO THYROID[12,13] 
Comprises <1% of thyroid malignancies. Renal cell carcinoma is 
the most common primary responsible for twenty three percent cases. The 
other common primary sites are breast (16percent), lung (15percent), 
melanoma (5percent), colon (4.5percent) and larynx (4.5percent). 
Diagnosis is by FNAC. Treatment is mainly palliative. Surgery may be 
indicated in case of obstructive symptoms. 
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2.5 DIAGNOSTIC STUDIES 
LABORATORY INVESTIGATION[14] 
THYROID STIMULATING HORMONE (TSH) 
Thyroid function tests can be used to diagnose asymptomatic 
thyroid dysfunction. TSH is routinely done if the thyroid nodule is more 
than one centimeter. A radio-isotope scan is indicated when the TSH is 
less than normal and this isassociated with a low risk of cancer. Thyroid 
cancers are infrequentlyassociated with thyrotoxicosis.Elevated TSH 
suggests hypothyroidism and isassociated with a greater risk of 
malignancy. 
THYROGLOBULIN (Tg)[8] 
Serum thyroglobulin (Tg) is a highly specific marker in the follow-
up of patients after initial treatment of thyroid cancer.Tg levels must be 
less than 2ng/mL while the patient is taking T4. If the patient is 
hypothyroid, it must be less than 5ng/mL. Thyroglobulin level >2ng/mL 
isindicative of residual thyroid tissue or metastatic deposits. Tg and 
antiTg anti-body levels are followed up at six month intervals in the 
beginning and then yearly until the patient is disease free. Rising titres of 
thyroglobulin or anti-Tg antibodies is highly suspicious of recurrence of 
the disease. 
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CALCITONIN 
The serum calcitonin level should be measured whenever there is a 
suspicion of medullary carcinoma. Patients with sporadic medullary 
carcinoma have a high baseline calcitonin level, but it is normal in thirty 
percent of patients with familial medullary carcinoma or multiple 
endocrine neoplasia (MEN) type 2. After curative surgery for MTC, 
serum calcitonin levels fall to undetectable levels over several weeks. If 
they remain elevated postoperatively, this is usually an indicator of 
residual cancer, either from local lymph node spread or from distant 
metastases. If previously undetectable or very low postoperative serum 
calcitonin levels are found to have increased, disease recurrence or spread 
is highly likely and further diagnostic evaluation is warranted. 
RADIOLOGICAL IMAGING[15] 
ULTRASOUND 
Ultrasound imaging is central to the investigation of most thyroid 
nodules Ultrasound is commonly used to assist in FNAC. It can be used 
for monitoring patients who are managed conservatively. Ultrasound 
featuresthat are suggestive of malignancy are the presence of micro-
calcifications, increased vascularity, irregular borders, hypoechogenicity 
and having a shape with height more than width on transverse view. 
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Patterns of sonographic features may be used to classify a given thyroid 
nodule as having high, intermediate, low, or very low suspicion for 
malignancy. When combined with the size of the nodule, these 
characteristics can be used to guide decisions to proceed with FNA 
biopsy. When a thyroid nodule is detected, it also is appropriate to assess 
the neck sonographically for pathologic adenopathy. If pathologic nodes 
are detected, biopsy may be targeted to the pathologic node. If metastatic 
thyroid cancer is found in a node, surgical planning may proceed from 
there.  
USG FEATURE SENSITIVITY (%) SPECIFICITY (%) 
Microcalcification 26 – 59 86 - 95 
Hypoechogenicity 27 - 87 43 - 95 
Irregular margins 17 - 78 39 - 85 
Increased vascularity 54 - 74 79 - 81 
Taller than wider shape 33 93 
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Fig 9: USG feature of malignant thyroid nodule (hypoechogenicity, 
irregular margins and calcification) 
COMPUTED TOMOGRAPHY AND MAGNETIC RESONANCE 
IMAGING 
Theyare useful in evaluating local extension in cases of thyroid 
tumors. It is particularly suitable for a suspicious nodule with bulky 
cervical lymphadenopathy. It is also useful for post-operative monitoring. 
CT is also helpful in preoperative evaluation of larger thyroid masses that 
are believed to have a sub-sternal component based on physical 
examination, ultrasound or chest radiograph. 
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RADIOISOTOPE SCANNING 
RAI is indicated for thyroid nodules more than one centimeter in 
size that are associated with a decreased serum TSH level. Technetium-
99m pertechnetate (99mTc) is absorbed quicklyby follicular cells. 
However it does not undergoorganification. 99mTc has a brief halflife 
and smallradiationdose. Its rate of uptake shows whether the nodules are 
hyperfunctioning (“hot”) or hypofunctioning (“cold”). 99mTc is also 
taken up by uptake salivary glands and major vascular structures, hence 
the results are carefully interpreted. 
Iodine scintigraphy with I123 and I131 is used to estimate the 
functional status of the gland. I123 and I131 are taken up by follicular cells 
and organified.I123 produces small dosage of radiation (30 mrad) with a 
brief half-life of twelve to thirteen hours. 
 I131 has a lengthier half-life of eight days and 
releasesgreaterintensities of beta radiation. It is ideal for imaging thyroid 
cancer. It is the ‘screening modality of choice’ for the assessment of 
metastases. Malignancy is present in 15% to 20% of cold nodules and in 
less than 5% of hot nodules.  
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Fig 10: Radioiodine scan showing normal thyroid uptake 
FINE NEEDLE ASPIRATION CYTOLOGY (FNAC)[15] 
FNAC is a key investigativeprocedure in theassessment of thyroid 
nodules. Patients with nodules having high-risk or intermediate-risk 
sonographic features should undergo FNAC if the nodules are 1 cm or 
larger in size, patients with nodules with low-risk sonographic features 
should undergo FNAC if the nodules are 1.5 cm or larger, and patients 
with nodules with very low suspicion sonographic features should 
undergo FNA biopsy if the nodules are 2 cm or larger.  
FNAC is performed using a twenty-three to twenty-seven gauge 
needle and may be performed with capillary or suction technique. It is 
associated with a low frequency of complications, while maintaining 
diagnostic accuracy. USGguided FNAC can be donefor 
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palpableheterogenous nodules, and for non-palpable swellings.Results of 
FNAC should be reported using the Bethesda System for Reporting 
Thyroid Cytology.  
BETHESDA 
SCORE 
CATEGORY RISK OF 
MALIGNANCY (%) 
1 Not satisfactory 1% - 4% 
2 benign 0% - 3% 
3 Atypia or follicular lesion of 
unknown significance 
5% - 15% 
4 Follicular neoplasm / suspicious 
for follicular neoplasm 
15% - 30% 
5 Suspicious for malignancy 60% - 75% 
6 malignant 97 %- 99% 
 
Papillary carcinoma has discrete cellular cytologic characteristics 
that make FNAC extremely accurate in securing this particular diagnosis. 
In contrast, the diagnosis of FTC is not made based on cellular features 
but instead on demonstration of capsular or vascular invasion by 
follicular cells. This architectural finding cannot be determined by 
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FNAC. Although FTCs do not have the same cytologic appearance as 
benign thyroid tissue, they often are categorized as suspicious for 
follicular neoplasm, and the diagnosis not made until final pathology is 
available.  
Another issue that must be understood is sampling error. A fine 
needle by definition is sampling only a small portion of a lesion. The 
false-negative rate of FNAC is 1% to 6%. 
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2.6 MANAGEMENT OF WELL-DIFFERENTIATED THYROID 
CARCINOMA 
The mainstay of management of well-differentiated carcinoma 
(WDC) is surgery.  
SURGERIES FOR WELL-DIFFERENTIATED CARCINOMA 
1. Total thyroidectomy – removal of entire gland with capsule. 
2. Near-total thyroidectomy – entire gland is removed preserving a 
small portion near the posterior capsule of the gland. 
3. Hemi-thyroidectomy – removal of ipsilateral lobe containing the 
lesion along with the isthumus. 
 
Total thyroidectomy removes all malignant tissue, but there is no 
normal thyroid tissue. So the patient requires life-long thyroid hormone 
supplementation. Also there is thehazard of bilateral injury to nearby 
important structures. Alternatively, conservative procedures may leave 
residual cancer.  
 
The current recommendation for near-total or total thyroidectomy 
are[16]: 
1) Prinary tumor greater than 1.5 cm. 
2) Nodules on the opposite lobe. 
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3) Metastasis. 
4) History of radiotherapy to the head and neck. 
5) History of differentiated thyroid carcinoma in a first-degree 
relative. 
6) Age above forty-five years. 
7) Tumors (4cm) with marked atypia. 
8) Unfavourable histology – tall cell variant, diffuse sclerosing 
variant, poorly differentiated, Hurthle cell carcinoma and follicular 
cancer (except microinvasive). 
 
 
Fig 11: Intra-operative picture of MNG 
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Fig 12: Recurrent laryngeal nerve 
Advantages of total thyroidectomy in well-differentiated carcinomas 
are: 
1) Better survival rate even for lesions >1.5cm. 
2) Low recurrence rate and prevention of recurrence in contralateral lobe. 
3) Decreased incidence of pulmonary metastasis. 
4) Mortality and morbidity is similar to lobectomy. 
5) Enhanced sensitivity of Tgas anindicator for persistent/recurrent 
disease. 
6) Radioactive iodine can be used to treat persistent / recurrent disease. 
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Hemithyroidectomy is done in differentiated cancers <1.5 cm in 
size without extrathyroidal extension and no distant metastasis. 
 
Fig 13: Thyroid bed following total thyroidectomy 
ARGUMENTS FAVOURING HEMITHYROIDECTOMY 
1) Differentiated thyroid cancer is an indolent disease and in a majority 
of patients has a very low recurrence and mortality rate. 
2) Hypoparathyroidism and damage to recurrent laryngeal nerve are 
potential problems of total thyroidectomy. 
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LYMPH NODE DISSECTION 
Approximately eighty percent of papillary thyroid carcinoma 
patients have microscopic regional lymph nodal metastasis. Adjuvant 
radioactive iodine ablation of occult micro-metastasis can be 
done.Palpable enlargement of nodes is seen in twenty to thirty percent of 
adults and is arationalization for lymph node dissection[17]. As the central 
group or level VI lymph nodes are mainly involved in thyroid 
malignancy, it is recommended that dissection of these groups of nodes 
be done in all cases of WDC. Studies have demonstrated an improved 
survival rate and reduced recurrence rate after prophylactic central 
compartment dissection[17,18,19]. The current American Thyroid 
Association Guidelines recommends a staging or prophylactic level VI 
dissection for all cases undergoing thyroidectomy for well-differentiated 
thyroid cancer. 
LATERAL NECK NODE DISSECTION 
Dissection of lateral jugular nodes (levels II-V) is vitalfor nodes 
involved by disease. Level based resection of lateral neck nodes is 
preferred over “berry picking”. Studies show that there is no 
improvement in survival rate following prophylactic lateral neck node 
dissection. However, followup of patients by detailed examination and 
USG, can recognize patients with lateral neck nodal disease that can then 
be properly treated by therapeutic compartmental node dissection. 
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POST OPERATIVE MANAGEMENT OF DIFFERENTIATED 
THYROID CANCER AND FOLLOW UP 
Thyroid Hormone / TSH suppression 
Thyroxine (T4) replacement therapy for patients who underwent 
total or near-total thyroidectomy suppresses TSH thereby eliminating the 
stimulus for any residual tumor cells. TSH suppression reduces tumor 
recurrence rates, particularly in young patients with papillary and 
follicular thyroid cancer. The goal of therapy should be to keep TSH level 
at around 0.1mU/L in low risk patients, or <0.1mU/L in high risk 
patients. 
Thyroglobulin (Tg) measurement 
Thyroglobulin is a highly specific marker for follow up. Tg levels 
should be below 2ng/mL ifthe patient is on T4 and <5ng/mL if the patient 
is hypothyroid. Thyroglobulin >2ng/mL is indicative of residual normal 
thyroid tissue or metastatic deposits. Tg and antiTg anti-body levels are 
estimated bi-annually in the beginning and then yearly. Rising titres is 
highly suspicious of recurrence of disease. 
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Imaging modalities 
A USG of the neck and CT or MRIscanof the neck and 
mediastinum is done in high risk patients for promptdiscovery of any 
recurrent or persistent disease. 
Radioactive iodine scan 
Post surgery screening and radioactive iodine I131 is more sensitive 
for detecting metastasis. T4 therapy is discontinuedfor four to six weeks 
before scanning with I131. During that period, patients are put on T3 to 
reduce the incidence of hypothyroidism. T3, having ashorter half-life than 
T4, iswithdrawn for two weeks to permit TSH levels to increase prior to 
treatment. Hypo-iodide diet is advised throughout thisphase. The 
standardpractice involves administering a screening dose of about 2mCi 
of I131 and quantifying uptake twenty-four hours later. The uptake is less 
than 1 percent after total thyroidectomy. A “hotspot” in the neck after 
primary screeningdenotes residual normal tissue. If a significant uptake is 
shown, a therapeutic radio-ablative dose of I131must be given to patient.  
RADIOACTIVE IODINE ABLATION (RIA) 
Radio-iodine therapy given as I131 is a veryefficient nonsurgical 
treatment for well-differentiated thyroid cancer. I131 emits beta 
radiationwhich destroys cancer cells. I131 uptake is reliant onsufficient 
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stimulation by TSH.Radio-iodine ablation is used increasingly post-
operatively in treatment of welldifferentiated thyroid carcinoma. The goal 
is to prevent loco-regional recurrence and destroy residual tissue. 
Studies[16] show anadvantage with I131 ablation in cases with a) tumors 
>1.5cm, b) multifocal tumors, c) residual disease and d) nodal metastases. 
AMERICAN THYROID ASSOCIATION GUIDELINES FOR RIA 
1) Stage III or IV disease. 
2) Stage II disease, younger than 45 years. 
3) Most of the patients older than 45 years. 
4) Selected patients with stage I disease – tumors >1.5 cm, multifocal, 
residual disease, nodal metastasis, vascular invasion and 
intermediately differentiated histology. 
Post-operative ablation is done 6 weeks after surgery. 
DOSE: Residual / recurrent thyroid bed disease – 150mCi  
Diffuse lung metastasis <150mCi. 
Some patients may need another I131 treatment after 6-12 months until 1 
or 2 negative scans are obtained. 
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Side effects of radio-iodine 
Short term complications include radiation thyroiditis, painless 
neck edema, sialoadenitis, nausea, tumor hemorrhage, temporary bone 
marrow depression and amenorrhea / oligomenorrhea. Late complications 
include secondary malignancies in bone, soft tissue, colo-rectal, salivary 
glands and leukemia. 
ROLE OF RADIOTHERAPY AND CHEMOTHERAPY FOR WDC 
Radiotherapy is sometimesnecessary to control unresectable, 
locally  invasive or recurrent tumor and to treat skeletal metastasis. Single 
and multi-drug chemotherapeutic agents have been used with limited 
success in disseminated thyroid carcinoma. The frequently used drugs are 
Adriamycin and taxol. 
MANAGEMENT OF PATIENTS WITH METASTATIC DISEASE 
The preferred treatment for metastatic disease includes the 
following: 
1) Surgical excision of loco-regional disease -with sparing of vital 
structures.  
2) External beam radiation.  
3) Surveillance of patients with stable asymptomatic disease. 
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4) Tentative chemotherapeutic trials. 
5) A small portion of patients may benefit from radio frequency ablation; 
ethanol ablation or chemo-embolization. 
TREATMENT OF PULMONARY METASTASIS 
The management of patients with pulmonary metastasis depends 
uponmetastatic lesion size, avidity of radioiodine uptake and response to 
prior therapy. Pulmonary micro-metastases are treated with radioiodine 
therapy, given every six to twelve months as long as disease continues to 
respond. Radioiodine is also used to treat larger pulmonary metastases if 
they are iodine avid. Non radioiodine avid pulmonary disease requires 
chemotherapy withcisplatin and doxorubicin. 
MANAGEMENT OF PATIENT WITH BONE METASTASIS 
The management of patients with bone metastasis depends 
onseveral factors. Studies show abetter survival rate associated with 
complete surgical resection of isolated bone metastasis, particularly in 
patients younger than 45 years of age. Radioiodine therapy can also be 
used for iodine-avid bone metastasis and is associated with better 
survival. External beam radiation can be given when skeletal metastatic 
lesions produce severe pain, fracture or neurologic complications. Un-
resectable painful lesions are treated by a combination of options or 
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individual treatment like radioiodine, external beam radiotherapy, intra-
arterial embolization, radio-frequency ablation, periodic zoledronate or 
pamidronate infusions or bone seeking radio-pharmaceuticals such as 
strontium-8 or samarium-153.  
 
Fig 14: Cervical vertebral metastasis 
TREATMENT OF BRAIN METASTASIS 
Brain metastasis carries a poor prognosis. Surgical excision and 
radiotherapy is the mainstay of treatment. Targeted therapy (like radio-
surgery) is employed to limit the radiation exposure of the surrounding 
brain tissue. Radioiodine can be used for CNS metastasis that take up 
radio-iodine. 
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AJCC CLASSIFICATION OF THYROID CANCER[20] 
PRIMARY TUMOR (T) 
TX: Primary tumor cannot be assessed 
T0: No evidence of primary tumor 
T1: Tumor ≤2cm in diameter, limited to thyroid 
T2: Tumor >2cm but <4cm in diameter, limited to thyroid 
T3: Tumor >4cm in diameter limited to thyroid, or any tumor with 
minimalextra-thyroidal invasion. 
T4a: Any size tumor extending beyond capsule to invade subcutaneous 
soft tissue, larynx, trachea, esophagus, or recurrent laryngeal nerve, or 
intra-thyroidal anaplastic cancer 
T4b: Tumor invading prevertebral fascia, or encasing carotid artery or 
mediastinal vessels; or extra-thyroidal anaplastic carcinoma 
REGIONAL LYMPH NODES (N) 
NX: Regional lymph nodes cannot be assessed 
N0: No regional lymph node metastasis 
N1: Regional lymph node metastasis 
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N1a: Metastases to level VI nodes 
N1b: Metastases to unilateral, bilateral, or contralateral cervical or 
superior mediastinal lymph nodes 
DISTANT METASTASIS (M) 
MX: Distant metastases cannot be assessed 
M0: No distant metastasis 
M1: Distant metastasis 
STAGE GROUPINGS 
PAPILLARY AND FOLLICULAR CARCINOMA 
STAGE TNM 
<45 y   
I  Any T, any N, M0  
II  Any T, any N, M1  
≥45 y   
I  T1, N0, M0  
II  T2, N0, M0  
III  T3, N0, M0; T1–3, N1a, M0  
IVA  T4a, N0–1a, M0; T1–4a, N1b, M0  
IVB  T4b, any N, M0  
IVC  Any T, any N, M1  
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MEDULLARY CARCINOMA 
STAGE TNM 
I  T1, N0, M0  
II  T2–3, N0, M0  
III  T1–3, N1a, M0  
IVA  T4a, N0–1a, M0; T1–4a, N1b, M0  
IVB  T4b, any N, M0  
IVC  Any T, any N, M1  
 
ANAPLASTIC CARCINOMA 
STAGE TNM 
IVA  T4a, Any N, M0  
IVB  T4b, Any N, M0  
IVC  Any T, Any M, M1  
 
PROGNOSIS OF WELL-DIFFERENTIATED CARCINOMA 
Papillary carcinomais associated with 90%-95% long-term disease-
free survival; follicular carcinoma with70%-80% long-term disease-free 
survival. 20% of patients having follicular cancer develop local 
recurrence and a small proportion develop distant metastasis. 
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PROGNOSTIC FACTORS 
AMES criteria (Lahey Clinic): based on age, metastatic disease, 
extra-thyroidal extension and size. 
 Low mortality risk High mortality risk 
A: age Men less than 41 years 
Women <51 years 
Men greater than 41 
years 
Women >51 years 
M: metastasis Absent Present 
E: extent of primary 
tumor 
Intrathyroidal papillary 
cancer; Follicular 
cancer with minor 
capsular involvement 
Extrathyroidal 
papillary cancer; 
Follicular cancer with 
major capsular 
involvement 
S: size of primary 
tumor 
<5 cm ≥ 5 cm (regardless of 
extent) 
 
AGES criteria (Mayo Clinic): based on age, grade of tumor, 
extent and size. 
Score = (0.05 x Age [if age >40] + 1 [if grade 2] + 3 [if grade 3 or 
4] + 1 [if extra-thyroidal] + 3 [if distant metastasis] ) + (0.2 x tumor size 
[maximum diameter in cm]) 
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20 year survival score 
<3.99 = 99% 
4-4.99 = 80% 
5 - 5.99 = 67% 
>6 = 13% 
The MACIS scale is a more sophisticated post-operative scale.It 
includes distant metastasis, age at presentation, completeness of original 
surgical resection, extra-thyroidal invasion and size of original lesion (in 
cm). 
OTHER PROGNOSTIC SCORING SYSTEMS 
 Ohio state: size, cervical metastasis, multiplicity, invasion, distant  
metastasis 
 Sloan–Kettering: age, histology, size, extension, metastasis 
 NTCTS: size, multifocality, invasion, differentiation, cervical 
metastasis, extra-cervical metastasis 
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METASTASIS 
Approximately 33%-61% of patients with PTC have cervical 
lymph node involvement at the time of diagnosis, whereas in follicular 
cancers, it is between 5%-20%. Only a tiny proportion of patients have 
metastatic disease during initial presentation, which is a strong predictor 
of very poor outcome. 
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3. MATERIALS AND METHODS 
3.1 Type of study      : Prospective and Observational Study 
3.2Study approval  :  Prior to commencement of this study –  
     Thesis & Ethical Committee of Madras  
     Medical College and Rajiv Gandhi  
     Government General Hospital, Chennai  
     has approved the thesis protocol. 
3.3 Place of study     : Rajiv Gandhi Government General  
     Hospital, Chennai. 
3.4 Period of study  : Duration starting from 01 August 2015 to  
     31 July 2016 
3.5  Sample size        :  50 cases  
3.6 Selection of patients:   
a)  Inclusion criteria- Patients havingclinically palpable 
thyroid nodule at initial presentation. 
b) Exclusion criteria –1.Patients having non-palpable thyroid 
nodules.2.Patientswhose FNAC samplesturned out to 
beunsatis factory.  
3.7 Study procedure: 
All the necessary information regarding the study was explained to 
the patients or their valid guardian. Informed written consent was taken 
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from the patientsready to participate in the study. Detailed history was 
taken from the study group to establish proper diagnosis as per the 
proforma (Annexure 1). Thorough physical examination was done in each 
case.FNAC, USG neck and Thyroid function test was done for all the 
patients.  Data collection sheets were filled in by the investigator. All of 
the preoperative factors related to the patient were noted down in the data 
sheet.Patients were then explained about their disease process and the 
possible line of management. After proper evaluation and preparation, 
patients who required surgical management were taken up for surgery. 
Strict aseptic precautions were followed during the operation. Meticulous 
techniques were practiced as far as possible. The operation procedure and 
related peroperative factors were observed directly and recorded in the 
data collection sheet instantly. The post operative HPE report was 
collected. After completing the collection of data it was compiled in a 
systematic way. 
 
3.8  Ethical consideration 
  
All the patients/ legal guardians were given an explanation of the 
study and about the investigative and operative procedures with their 
merits and demerits, expected results, and possible complications. If 
he/she agreed then the case had been selected for this study. The study 
did not involve any additional investigation or any significant risk. It did 
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not cause economic burden to the patients. The study was approved by 
the institutional ethical committee prior to commencement of data 
collection. Informed consent was taken from each patient/guardian. Data 
were collected by approved data collection form. 
 
3.9 Data collection 
Data were collected by pre-tested structured questionnaire. Data 
were collected from all the respondents by direct interview after 
getting informed written consent from them or from their legal 
guardian. 
 
3.10 Data analysis 
Data analysis was done both manually and by using computer. 
Calculated data was arranged in systemic manner and presented in 
various table and figures. Statistical analysis wasdone. Results on 
continuous measurements are presented as Mean ± SD (Min-Max) and 
results on categorical measurements are presented in Number (%). 
Significance is assessed at 5% level of significance. Chi-square test has 
been used to find the significance of study parameters on categorical 
scale between two or more groups.  
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SIGNIFICANT FIGURES: 
+ Suggestive significance (P value: 0.05<P<0.10) 
* Moderately significant (P value: 0.01<P<0.05) 
** Strongly significant (P value: P≤0.01) 
 
STATISTICAL SOFTWARE 
 The statistical software namely SAS 9.2, SPSS 15.0, Stats 10.1, 
MedCalc 9.0.1, Systat 12.0 and R environment ver.2.11.1 were used for 
the analysis of data and Microsoft Word and Microsoft Excel have been 
used to generate graphs, tables, etc. 
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OBSERVATION AND RESULTS 
 This was a prospective study done in the Institute of General 
Surgery at Madras Medical College, Chennai. The study period was 
August 2015 to July 2016. 
 Total number of cases = 50 
 Total number of cases confirmed with malignancy = 13 
STUDY DESIGN 
 A prospective study with a sample size of 50 patients was 
conducted at the Institute of General Surgery, Madras Medical College, 
Chennai. Patients with palpable thyroid nodules were included. The 
preoperative clinical, radiological and TSH levels were analyzed and a 
cancer risk score was assigned to each patient as per the scoring system 
designed. This score was compared with the post-operative HPE report to 
predict the risk of malignancy. The observed results were subjected to 
statistical analysis. The following observations were made. The risk 
factors used in the scoring system were assigned scores based on the 
existing McGill Thyroid Nodule Scoring System. The parameters were 
assigned scores based on the previously demonstrated sensitivity and 
specificity of each parameter for carcinoma. A maximum cancer risk 
score of  26 is attainable with this scoring system. 
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THE SCORING SYSTEM 
1. CLINICAL DATA:  
FACTOR: ASSIGNED SCORE: PATIENT’S SCORE: 
AGE (>45 YEARS) 1  
GENDER (MALE) 1  
EXPOSURE TO IONIZING 
RADIATION (+) 
3  
FAMILY HISTORY OF THYROID 
MALIGNANCY (+) 
3  
CONSISTENCY OF GLAND 
(HARD) 
2  
TSH LEVEL (>1.4mIU/L) 1  
2. ULTRASONOGRAM OF NECK: 
FACTOR: ASSIGNED SCORE: PATIENT’S SCORE: 
SHAPE  (TALLER THAN 
WIDE) 
1  
SIZE 2-2.9CM 2  
3-3.9CM 3 
4CM AND 
ABOVE 
4 
NODULARITY MULTIPLE 1  
SOLITARY 2 
ECHOGENICITY 
(HYPOECHOIC) 
1  
CALCIFICATION (+) 1  
CERVICAL LYMPH NODES 
(+) 
2  
VASCULARITY INCREASED 1  
3. FNAC: 
FEATURE: ASSIGNED SCORE: PATIENT’S SCORE: 
BENIGN 1  
SUSPICIOUS OF 
MALIGNANCY 
2 
MALIGNANT 3 
                             TOTAL SCORE:  
Table 1: Age distribution of patients 
 
 
 
In our study 50 patients were included out of which 25 pati
were aged more than 45 years and 25 patients were aged less than 
years. Among the patients proven to have malignancy, 6 were aged 
45 years. Patients over 
 
 
AGE IN YEARS 
<45 (0) 
>45 (1) 
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RESULTS 
AGE DISTRIBUTION 
 
 
45 years of age were given a score of 1.
BENIGN MALIGNANT 
18 7 
19 6 
>45yrs(1)
50%
<45yrs(0)
50%
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ents 
45 
over 
 
TOTAL 
25 
25 
Table 2: Gender distribution of patients
 
 
 
 
 
 
 Among the 50 patients 44 were female and 6
Among the cases proved to be malignant, 3 were male. Male gender was 
given a score of 1. 
 
 
GENDER 
FEMALE (0) 
MALE (1) 
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GENDER DISTRIBUTION 
 
 
 
 
Male(1)
12%
Female(0)
88%
BENIGN MALIGNANT 
34 10 
3 3 
 
 
 were male. 
TOTAL 
44 
6 
FAMILY HISTORY OF MALIGNANCY
Table 3: Distribution 
FAMILY 
HISTORY OF 
MALIGNANCY 
PRESENT (3) 
ABSENT (0) 
 
 Among the 50 patients, only 1 patient had a family history of 
thyroid malignancy and this patient was also diagnosed with malignancy 
post operatively. 
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according to family history of malignancy
BENIGN MALIGNANT 
0 1 
37 12 
 
Yes(3)
 
 
TOTAL 
1 
49 
 
No
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EXPOSURE TO IONIZING RADIATION 
 
Table 4: Distribution according to history of exposure to 
ionizing radiation 
 
 
 Among the patients studied, none had history of exposure to 
ionizing radiation. The presence of this history was given a score of 3. 
 
 
 
 
 
 
 
 
 
EXPOSURE TO 
IONIZING 
RADIATION 
BENIGN MALIGNANT TOTAL 
PRESENT (3) 0 0 0 
ABSENT (0) 37 13 50 
Table 5: Distribution of patients with hard consistency of gland
HARD 
CONSISTENCY 
PRESENT (2) 
ABSENT (0) 
Among the 50 patients studied, 13 patients on clinical 
had hard consistency of the thyroid gland. Among those diagnosed with 
malignancy, 12 had hard consistency of gland. The presence of hard 
consistency was given a score of 2.
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CONSISTENCY OF GLAND 
BENIGN MALIGNANT 
1 12 
36 1 
 
 
 
Hard(2)
26%
No 
74%
 
TOTAL 
13 
37 
 
examination 
Table 6: Distribution of patients depending upon TSH level
TSH LEVEL 
> 1.4 mIU/L (1) 
< 1.4 mIU/L (0) 
  
Among the 50 patients studied, 29 had serum TSH level 
>1.4mIU/L and 21 had TSH level <1.4mIU/L. Among those diagnosed to 
have malignancy, 12 had TSH level >
>1.4IU/L was given a score of 1 in our study.
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TSH LEVEL 
 
BENIGN MALIGNANT 
17 12 
20 1 
 
 
1.4IU/L. A serum TSH level 
 
>1.4mIU/L (1)
58%
<1.4mIU/L
42%
  
TOTAL 
29 
21 
 
Table 7: Distribution of patients with USG feature of taller 
TALLER THAN 
WIDER SHAPE 
PRESENT (1) 
ABSENT (0) 
 39 patients had USG feature of taller than wider shape of 
their thyroid. Among these patients 10 patients were diagnosed with 
malignancy post operatively.This feature was given a score of 1 in our 
scoring system. 
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SHAPE OF THE GLAND 
than wider shape 
BENIGN MALIGNANT 
29 10 
8 3 
 
 
 
Yes (1)
78%
No
22%
TOTAL 
39 
11 
 
Table 8: Distribution based on size of the gland determined by USG
SIZE 
2 – 2.9 CM (2) 
3 – 3.9 CM (3) 
≥ 4 CM (4) 
 
 Among the patients diagnosed with malignancy, 3 patients had size 
of gland between 2
≥4 cm. Each of these sizes were given a score of 2, 3 and 4 respectively. 
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SIZE OF THE GLAND 
 
BENIGN MALIGNANT 
8 3 
15 4 
14 6 
 
–2.9 cm, 4 had size between 3-3.9 cm and 6 had size 
2-2.9 CM (2)
19%
3-3.9 CM (3)
39%
4 CM AND 
ABOVE (4)
42%
 
TOTAL 
11 
19 
20 
 
 
Table 9: Distribution 
NODULARITY 
SOLITARY (2) 
MULTIPLE (1) 
 
 26 patients had solitary nodular goiter and 24 patients had 
multinodular goiter. 7 patients with malignancy had solitary nodule and 6 
patients with malignancy had multinodular goiter. Solitary nodule was 
given a score of 2 and multinodularity was given a score of 1, both of 
which were determined by USG.
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NODULARITY OF GLAND 
based on nodularity
 
BENIGN MALIGNANT 
19 7 
18 6 
 
 
MULTIPLE
48%SOLITARY
52%
 
TOTAL 
26 
24 
 
Table 10: Distribution based on USG determined echogenicity of 
HYPOECHOGENICITY
PRESENT (1) 
ABSENT (0) 
 
 39 patients showed the presence of hypoechoic nodules on USG. 
All the patients diagnosed with malignancy had hypoechoic nodules on 
USG. 
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ECHOGENICITY OF GLAND 
gland 
 
 BENIGN MALIGNANT 
26 13 
11 0 
 
 
Yes(1)
78%
No
22%
TOTAL 
39 
11 
 
Table 11: Distribution based on presence of calcification 
CALCIFICATION 
PRESENT (1) 
ABSENT (0) 
 
 13 patients had intra
Among these patients 10 were 
operatively. The presence of calcification on USG was given a score of 1.
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CALCIFICATION OF GLAND 
within the gland 
 
BENIGN MALIGNANT 
3 10 
34 3 
 
 
-glandular calcification determined by USG. 
confirmed to have malignancy post
Yes(1)
26%
No
74%
 
TOTAL 
13 
37 
 
-
 
79 
CERVICAL LYMPH NODE INVOLVEMENT 
Table 12: Distribution based on cervical lymph node involvement 
 
CERVICAL 
LYMPHADENOPATHY 
BENIGN MALIGNANT TOTAL 
PRESENT (2) 9 11 20 
ABSENT 28 2 30 
 
 
 
 
 Of the 50 patients evaluated, 20 had cervical lymphadenopathy 
confirmed radiologically and 30 did not have lymphadenopathy. 11 
patients with proven malignancy had lymphadenopathy. The presence of 
cervical lymphadenopathy was given a score of 2. 
 
No 
60%
Yes (2)
40%
VASCULARITY OF THE GLAND
Table 13: Distribution based on vascularity of gland
VASCULARITY 
INCREASED (1) 
NORMAL (0) 
  
 Among the patients studied, 33 patients showed 
vascularity of the gland on USG. All the 13 patients with malignancy had 
increased vascularity. The presence of increased vascularity was given a 
score of 1. 
 
 
Yes (1)
66%
80 
 
 
BENIGN MALIGNANT 
20 13 
17 0 
 
No
34%
 
TOTAL 
33 
17 
 
increased 
FINE NEEDLE ASPIRATION CYTOLOGY
Table 14: Distribution based on FNAC report
FNAC REPORT
BENIGN (1)
SUSPICIOUS OF MALIGNANCY (2)
MALIGNANT (3)
 
 The FNAC report of 30 patients under study was found to be 
benign, 13 patients had a lesion suspicious of malignancy and 7 patients 
had outright malignancy. Among 
suspicious of malignancy, 6 out of 7 turned out to be malignant. Benign, 
suspicious of malignancy and malignant lesions were given a score of 1, 
2 and 3 respectively.
26%
14%
81 
 
 NUMBER OF CASES
 30 
 13 
 7 
the patients whose FNAC report was 
 
60%
BENIGN
SUSPICIOUS OF 
MALIGNANCY
MALIGNANT
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Table 15: Final pathology according to the scoring system 
SCORE BENIGN MALIGNANT 
PERCENTAGE 
OF 
MALIGNANCY 
(%) 
1 0 0 0 
2 0 0 0 
3 1 0 0 
4 1 0 0 
5 1 0 0 
6 3 0 0 
7 4 0 0 
8 5 0 0 
9 4 0 0 
10 4 0 0 
11 3 0 0 
12 4 1 20 
13 4 1 20 
14 2 1 33.33 
15 1 1 50 
16 0 3 100 
17 0 1 100 
18 0 3 100 
≥19 0 2 100 
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The scores ranged between 3 and 19, with a mean score of 11. The 
incidence of thyroid carcinoma for scores of 1 to 11 was 0% (0 out of 24 
patients), 12 to 13 was 20% (2 out of 10 patients), 14 to 18 was 75% (9 
out of 12 patients) and ≥19 was 100% (2 out of 2 patients). A score ≤11 
correlated with a 0% risk of malignancy, whereas a score>11 implied a 
54.166% risk of malignancy. This greater risk demonstrated for patients 
above a score of  >11 is statistically significant (p<0.0001, χ2 = 14.965, df 
= 1). 
Table 16: Score versus HPE report 
 POST OP HPE:  
TOTAL BENIGN MALIGNANT 
SCORE ≤11 26 0 26 
>11 11 13 24 
TOTAL 37 13 50 
 
Table 17: Result of Chi Square Test 
 Value df Asymp. Sig. 
 (2-sided) 
Yates Chi-Square 16.32 1 < 0.0001(S) 
Pearson Chi-Square 19.03 1 < 0.0001 (S) 
N no. of cases 50   
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 Thyroid nodules often present a considerable management 
dilemma for the thyroid surgeon, pathologist, endocrinologist, and patient 
alike owing to their diagnostic ambiguity. There is an imperative need for 
a reliable analytical test to help determine preoperatively the nature of a 
thyroid nodule, before committing patients to surgery. Ideally, such a test 
would yield a high PPV for carcinoma, affirming the need for surgical 
excision while representing a high degree of specificity, which would 
help limit the number of patients subjected to thyroid surgery and its 
potential morbidities for excision of benign nodules.  
Numerous attempts have been made to define clinical, sonographic 
and cytologicparameters useful for identifying patients at higher risk of 
malignancy. None of these parameters, however, have proven to be 
adequate on their own to guide clinical decision-making.  
The concept of a combined scoring system was previously 
proposed by Rago and colleagues[21], who calculated a risk score derived 
from both clinical and echographic parameters and applied it exclusively 
to indeterminate lesions to describe the individual possibility of 
malignancy.  
The McGill Thyroid Nodule Scoring system (MTNS)[22]was 
proposed which summated 22 parameters. A multidisciplinary team, 
using existing evidencebased risk factors for thyroid cancer, developed 
the MTNS. These risk factors were categorized into eight 
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clinical/laboratory parameters, eight imaging (sonography/ positron 
emission tomography [PET] scan) features and six histopathologic 
criteria.  
Our scoring system also incorporates 14 parameters based on 
clinical, sonological and pathological data. Each of the 14 parameters was 
assigned a relative point score according to the current supporting 
evidence for that variable and the degree to which it was felt to impact the 
pretest probability for cancer.This observational study was conducted 
among 50 patients admitted in the Institute of General Surgery, Madras 
Medical College and Rajiv Gandhi Government General Hospital, 
Chennai.  
CLINICAL PARAMETERS AND LABORATORY TESTS 
AGE  
 Increasing age is long recognized as a well-established threat for 
thyroid malignancy. Age >45 years is incorporated into the American 
Joint Committee on Cancer (AJCC) staging[20]. A study of the 
Surveillance, Epidemiology, and End Results (SEER database) found, 
among 9904 patients with papillary thyroid cancer (PTC), that age >45 
years was significantly associated with bad outcome on multivariate 
analysis[2]. Age >45 years was given a score of 1 in our study owing to 
limitations in specificity. 52% of malignant cases had age >45 years. 
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GENDER 
 It is well known that thyroid malignancies are more common in 
females than males. But male gender, itself, is a solid risk factor for 
carcinoma and hence was given a score of 1. In our study 3 out of 13 
patients diagnosed with malignancy were male (1:4.2) which is 
comparable to other studies.  
 
FAMILY HISTORY OF THYROID MALIGNANCY 
 A family history of thyroid cancer, or thyroid cancer in a first- 
degree relative, is also one of the few well-established risk considerations 
for carcinoma. Owing to the vast nature of support in the literature and 
the universally accepted nature of family history as a risk factor, it was 
also given 3 points within the scoring system[23]. In our study one patient 
had history of thyroid malignancy in mother, and this patient was also 
diagnosed with papillary cancer post operatively.  
 
EXPOSURE TO IONIZING RADIATION 
 Evidence of a linear dose–cancer association has been reported in 
studies of childhood survivors of the atomic bombings of Hiroshima and 
Nagasaki and in studies of children treated with either radiotherapy or 
iodine-131[24]. The Canadian National Dose Registry reported elevated 
standardized incidence ratios (SIRs) for thyroid cancer for both male (SIR 
1.35; 90% CI 0.97–1.75) and female (SIR 1.42; 95% CI 1.19–1.69) 
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radiation workers[25]. As little doubt exists with respect to this association, 
a history of significant previous radiation exposure was given a score of 3 
in the MTNS. None of the patients in our study had history of exposure to 
ionizing radiation. 
 
CONSISTENCY OF GLAND: 
 A number of authors have agreed that nodules that are felt to be 
‘‘stone’’ or ‘‘bone’’ hard on palpation indicate a higher likelihood of 
carcinoma. Raber[26] and colleagues demonstrated a predictive value of 
57% and a relative risk of 2.6 for thyroid carcinoma in the presence of 
this feature (95% CI 1.2–5.6). Hence score of 2 was assigned. 12 out of 
13 patients diagnosed with malignancy in our study had hard consistency 
of gland on clinical examination.  
 
TSH LEVEL 
 Elevated serum thyroid-stimulating hormone level, even within the 
higher end of the range, is associated with augmented risk of malignancy. 
A well-designed study of over 800 patients conducted by Haymart et 
al[27]showed that the risk of carcinoma was significantly greater when 
TSH levels were between 1.40 and 4.99 mIU/L compared to lower levels 
(35% vs 25%, p = 0.002). Based on these findings, TSH serum levels 
>1.4 mIU/L was incorporated into the scoring system and given a risk 
score of 1. In our study 12 out of 13 patients diagnosed with malignancy 
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had a serum TSH level >1.4mIU/L which is comparable to the results of 
Haymart et al, Fiore et al and Jonklaas et al. 
 
ULTRASONOGRAPHY[28,29,30.31,32] 
 Ultrasonography attempts to distinguish malignant from benign 
nodules.Many recent studies have discussed the importance of distinctive 
sonographic features as predictors of malignant thyroid nodules. 
 
SHAPE OF THE GLAND 
 When imaging a nodule in the transverse direction, height greater 
than width, has been correlated with increased likelihood of malignancy 
(specificity range of 60– 93%)[32]. This is believed to represent aberrant, 
aggressive growth across the natural horizontal growth planes within the 
thyroid gland. It is also a reflection of tumor compressibility by an 
ultrasound probe. The sensitivity and specificity of this finding are 
variable, thus a score of only 1 was assigned. However in our study 
92.30% of patients with malignancy demonstrated this feature on 
ultrasound. 
 
SIZE OF THE GLAND 
 Nodule size has been consistently associated with greater risk of 
malignancy. Tuttle and colleagues showed that nodules that were 
measured to be >4 cm to palpation had a 40% malignancy rate (vs 13% 
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for smaller lesions, p 5 .03). Raber and colleagues validated this 
correlation between size >4 cm and malignancy via sonography. Nodules 
measuring 3 cm or more on a sonogram conferred a 55% risk (vs 23% in 
smaller nodules, p , .0001) in another study. Yet smaller nodules(2 cm) 
have been demonstrated to represent a higher likelihood of cancer in 
other studies. To account for these discrepancies in the literature, we 
proposed that nodules of 2 to 2.9 cm be given a score of 2, 
nodulesof3to3.9cmascoreof3,and nodules >4cma score of 4 points. Our 
study too demonstrated a greater proportion of patients with malignancy 
(46%) having a size greater then 4 cm. 
 
NODULARITY OF THE GLAND 
 Risk of malignancy in generalized swelling is about 3% and in 
solitary nodule of thyroid is about 15%. In a study conducted by Lema 
L.E.K, M.R.Aziz, N.A.Mbembati, H.A.Mwakyoma, malignancy was 
found in 10% of solitary nodule thyroid and 5% of multinodular goiter. In 
our study 53.8% of patients with malignancy had a solitary nodule and 
46.2% demonstrated multinodular goiter. 
 
ECHOGENICITY, VASCULARITY AND CALCIFICATION OF 
GLAND 
Hypoechogenicity, increased Doppler flow and calcifications are 
the most widely recognized characteristics that increase the index of 
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suspicion for a malignant nodule. One study compounded the test 
characteristics for each feature of malignancy from seven additional 
studies and found hypoechogenicity to carry a 73% specificity, Doppler 
flow a 79% specificity andcalcifications a 91%specificity[28,29,31]. Because 
of high inter-observer variability and differing radiologic techniques, and 
because the various ultrasound findings are taken in constellation with 
one another, we assigned a score of 1 to each of these three features. In 
out study, 100 % of patients with malignancy demonstrated 
hypoechogenicity and increased vascularity of gland and 76.9% of 
patients with malignancy showed the presence of calcification within the 
gland. 
 
CERVICAL LYMPH NODE INVOLVEMENT 
 Cervical lymphadenopathy is a common presentation in thyroid 
malignancy. The presence of cervical lymph nodes on ultrasound 
increased the predictive value of diagnosing thyroid cancer in suspicious 
nodules. Mazzaferri et al[30] demonstrated a 53–61% incidence of cervical 
lymphadenopathy in thyroid cancers. In our study, the incidence of 
cervical lymph node enlargement among malignant patients was 76.92% 
and was assigned a score of 2. 
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FINE NEEDLE ASPIRATION CYTOLOGY 
 Cytologicatypia on FNAC has been shown to represent a higher 
likelihood of malignancy on a relatively consistent basis. In a study by 
Raparia et al, FNAC predicted malignancy with a sensitivity of 86.8%, a 
specificity of 67.0%, a negative predictive value of 87.5% and a positive 
predictive value of 65.5%[33,34,35]. Our study categorized FNAC report as 
benign, suspicious of malignancy and malignant and assigned a score of 
1, 2 and 3 respectively. In our study, 53.8 % of patients with malignancy 
had a corelation between their FNAC and post operative HPE finding. 
The remaining 46.2 % of patients had an FNAC report which was 
suspicious for malignancy but their post operative HPE turned out to be 
malignant. 
 
THE SCORING SYSTEM 
 Our scoring system carried a maximum score of 26. The observed 
scores ranged between 3 to 19, with a mean score of 11.  
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Score versus HPE status 
Predictive value for malignancy 
1 to 3 4 to 7 8 9 to 11 12 to 
13
14 to 
24.3%
13.5%
29.7%
21.6%
8.1%
0.0% 0.0% 0.0% 0.0%
15.4%
20
75
20 40 60 80
Percentage of malignancy (%)
 
 
18
≥19
0.0%
69.2%
15.4%
100
100
The incidence of thyroid carcinoma for scores of 1 to 11 was 0% (0 
out of 24 patients), 12 to 13 was 
75% (9 out of 12 patients) and 
 
 
In our study, all the malignant cases had a score >11. 70.2% of 
benign cases had a score 
The average risk of malignancy for patients with a score greater than the 
mean score of 11 was 54.166%. This greater risk demonstrated for 
patients above a score of 11 was also statistically significant (p<0.0001, 
χ
2 
= 14.965, df = 1). 
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≤11
70.2%
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20% (2 out of 10 patients), 14 to 18 was 
≥19 was 100% (2 out of 2 patients). 
Score versus cancer status 
≤11 and 29.8% of benign cases had a score >11. 
 
>11
29.8%
0%
100%
 
 
Benign
Malignant
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The scoring system showed a favorable characteristic on the 
receiver operator curve (ROC). The area under the curve showed 81.1% 
sensitivity which is similar to that of the MTNS scoring system[22]. 
Table 18: ROC curve analysis 
Test Result 
Variable(s) 
Area Std. 
Errora 
Asymptotic 
Sig.b 
Asymptotic 95% Confidence 
Interval 
Lower 
Bound 
Upper  
Bound 
Mean score .811 .059 .001 .695 .926 
MTNS 
score_ 
.943 .031 .000 .881 1.000 
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The sensitivity and specificity for carcinoma are 70.27% and 100% 
respectively. The positive and negative predictive values are 100% and 
43.83% respectively. In our study, a score ≥16 was associated with 100% 
risk of malignancy. 
In our study, 4 cases had pre-operative FNAC report as benign 
lesion. But all four patients had a score ≥15 according to our scoring 
system and their post operative HPE turned out to be malignant. Thus the 
scoring system helps to minimize the false-negative rates of FNAC. It can 
make pre-operative decision making much easier. Patients with a high 
score and thus a greater risk of malignancy can be carefully selected for 
surgery and a more vigilant post–operative follow up can be done. 
 
  
97 
5.2 LIMITATIONS OF THE STUDY 
 The study was carried out over a limited period of time with a 
restricted number of patients and there was lack of financial and 
infrastructural support, it could not have been large enough to be of 
reasonable precision. All the facts and figures mentioned here may 
considerably vary from those of large series covering wide range of time, 
but still then, as the cases of this study were collected from a tertiary level 
hospital in our country, this study has some credentials in applying a 
scoring system combining clinical, laboratory and sonological data, 
which are routinely documented pre-operatively, to predict the risk of 
malignancy in patients with thyroid nodules.  
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5.3 SUMMARY 
 Thyroid nodules are one of the frequently encountered diseases in 
the general surgery department. The incidence of malignancy in thyroid 
nodules is on the rise. Though there are many predictors of thyroid 
malignancy, none of them can conclusively predict the nature of a thyroid 
nodule. Our study aimed at evaluating a scoring system for predicting the 
risk of malignancy in thyroid nodules using clinical, laboratory and 
sonological data. The observations of this study can be summarized as 
follows: 
 Our scoring system had a maximum score of 26. The observed 
scores ranged from 3 to 19. 
 The incidence of thyroid carcinoma for scores of 1 to 11 was 0%, 
12 to 13 was 20%, 14 to 18 was 75% and ≥19 was 100%.  
 The mean score was found to be 11. The average risk of 
malignancy for a score ≤11 was 0% and for a score >11 was 
54.166%.  
 The sensitivity and specificity of the scoring system was 70.2% 
and 100% respectively. 
 The positive and negative predictive value for the scoring system 
was 100% and 43.83% respectively. 
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 The greater risk of malignancy demonstrated for patients above a 
score of 11 was statistically significant (p<0.0001, χ2 = 14.965, df = 
1). 
 The risk of malignancy increased with increasing scores and was 
found to be 100% for a score ≥16. 
 Among the risk factors studied, a family history of thyroid 
malignancy has a very high positive predictive value for 
development of thyroid carcinoma. 
 Thyroid carcinomas are also frequently associated with increased 
TSH levels. 
 Among the various USG features that predict malignancy, 
hypoechogenicity, calcification, increased vascularity and presence 
of cervical lymphadenopathy have a higher predictive value for 
malignancy. 
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5.4 CONCLUSION 
 This prospective observational type of study was conducted in 
Institute of General Surgery, Madras Medical College and Rajiv 
Gandhi Government General Hospital, Chennai, from 01 August 2015 
to 31 July 2016. It can be concluded from the findings of the study 
that this combined scoring system can serve as an accurate predictor 
for thyroid malignancy. It will help physiciansto  better assess the risk 
that a thyroid nodule is malignant, and therefore formulate clinical 
decisions accordingly, in conjunction with a more informed patient. 
This will also assist in the decision making with respect to the extent 
of surgery that will be performed: hemithyroidectomy or total 
thyroidectomy, with or without central compartment neck dissection. 
The scoring system brings high risk patients to the forefront and 
stands as an extremely powerful and valuable resource to surgeons to 
aid in their clinical decision making. 
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5.5 RECOMMENDATIONS 
On the basis of the findings of the study, the following 
recommendations can be made: 
 The scoring system can be introduced as a routine pre-operative 
assessment tool for patients presenting with thyroid nodules. 
 Patients having a high score can be subjected to further evaluation 
before final decision making regarding the appropriate surgery. 
 Further research is necessary in large scale for guidance regarding 
inclusion of additional risk factors to the scoring system thereby 
increasing its accuracy. 
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8.ANNEXURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANNEXURE – I: PROFORMA 
 
QUESTIONNAIRE: 
 
Name:      Age/Sex: 
Address:      Occupation: 
 
SYMPTOMS: 
Swelling in the neck- size, duration 
 
PAST HISTORY: 
Previous h/o surgery/ radiation/ chemotherapy 
 
FAMILY HISTORY: 
Thyroid malignancy+/- 
 
GENERAL EXAMINATION: 
 
VITAL SIGNS: 
       PR- 
       BP- 
       RR- 
 
LOCAL  EXAMINATION: 
Examination of  Thyroid gland-size, consistency, no. of nodules 
Examination of  cervical Lymph Nodes 
 
INVESTIGATIONS: 
FNAC 
USG NECK 
TSH LEVEL 
SURGERY DONE: 
POST-OP HPE 
 
 
ANNEXURE – II: INFORMATION SHEET AND CONSENT FORM 
INFORMATION SHEET 
TITLE: “EVALUATION OF A SCORING SYSTEM FOR PREDICTING 
THE RISK OF MALIGNANCY IN THYROID NODULES USING 
CLINICAL, LABORATORY AND SONOLOGICAL DATA 
Name of Investigator: Dr.S.Sadhana. Name of Participant: 
Purpose of Research :To evaluate the efficacy of a scoring system using 
clinical and laboratory data, ultrasound findings and fnac report for 
predicting the risk of malignancy in thyroid nodules. 
Study Design  :Prospective and Retrospective Observational Study 
Study Procedures :Patient will be subjected to routine investigations, 
Thyroid function test, USG and FNAC. 
Possible Risks :No risks to the patient 
Possible benefits: 
To patient :Patients treatment is tailored to their specific risk predictions. 
To doctor & to other people :If this study gives positive results, it can 
help determine the treatment protocol for patients undergoing thyroid 
surgeries. This will help in providing better and complete treatment to 
other patients in future. 
Confidentiality of the information obtained from you :The privacy of 
the patients in the research will be maintained throughout the study. In the 
event of any publication or presentation resulting from the research, no 
personally identifiable information will be shared 
Can you decide to stop participating in the study :Taking part in this 
study is voluntary. You are free to decide whether to participate in this 
study or to withdraw at any time 
How will your decision to not participate in the study affect you :Your 
decision will not result in any loss of benefits to which you are otherwise 
entitled. 
 
Signature of Investigator    Signature Of Participant 
 
Date :                                                                      Date: 
Place :                                                                      Place: 
Ma;tpy; gq;Nfw;gth;fhdjfty; mwpf;if 
 
Ma;tpd; jiyg;G:kUj;Jttptuq;fs;>Ez;zjph;tpy; ghpNrhjidtptuq;fs; kw;Wk; 
Ma;tfjfty;fisgad;gLj;jpijuha;Lfl;bapy; 
Vw;glf;$baGw;WNeha;f;fhdtha;igfzpf;fcjTk; xUkjpg;gPl;LKiwiagw;wpaMa;T.  
Ma;thshpd; ngah; : kU.r.rhjdh (mWitrpfpr;irMa;TgphpT) 
Ma;Tikak; : uh[Pt; fhe;jpmuRnghJkUj;Jtkid>nrd;id.  
 
,e;jMa;tpy; jq;fisgq;Nfw;fmiof;fpNwhk;. ,e;jjfty; mwpf;ifapy; 
$wg;gl;bUf;Fk; jfty;fs; jhq;fs; ,e;jMuha;r;rpapy; 
gq;Nfw;fyhkhNtz;lhkhvd;gijKbTnra;acjtpahf ,Uf;Fk;. ,e;jgbtj;jpy; 
cs;sjfty;fs; gw;wpcs;sre;Njfq;fisePq;fs; jaq;fhky; Nfl;fyhk;.  
,e;jMa;tpd; Nehf;fk; vd;d?  
ijuha;Lfl;bapy; Gw;WNeha; 
Vw;gLtjw;fhdtha;igkUj;Jttptuq;fs;>Ma;T$lNrhjidkw;Wk; Ez;zjph;tpy; 
ghpNrhjidjfty;fs; %yk; fz;lwpAk; kjpg;gPLmikg;Ggw;wpaMa;T. ,jdhy; 
rpfpr;irKiwkhwhJ (m) jhkjkhfhJ.  
Ma;TKiwfs;:  
tphpthdNeha;f; Fwpg;GfSk;>kUj;JtghpNrhjidfSk; Kiwahfnra;ag;gLk;. 
ijuha;Lfl;bcs;sth;fSf;Ffl;bapd; jd;ik>ijuha;L `hh;Nkhd; 
msT>Ez;zjh;TghpNrhjidtptuk; kw;Wk; fl;bapd; Ez;Zrpjputg;gbtghpNrhjidapd; 
jfty;fs; Nrfhpf;fg;gl;L ,e;jkjpg;gPLmikf;fg;gLk;. 
,e;jkjpg;gPl;ilmth;fSilamWitrpfpr;irf;Fgpd; fpilf;Fk; Ngj;jhyh[p 
mwpf;ifAld; xg;gpl;Lmth;fSf;FGw;WNeha; tUtjw;fhdtha;igfz;Lmwpag;gLk;.  
Ma;tpdhy; kf;fSf;FVw;gLk; ed;ikfs;:  
,e;jMa;tpd; Kbtpy; fpilf;Fk; jfty;fs; 
rKjhajpw;FgaDs;sjhfTk;>vjph;fhyj;jpy; NehahspfSf;FkUj;JtjPh;thfTk; mikAk;.  
jq;fsplkpUe;Jngwg;gLk; jfty;fspd; ek;gpf;ifj; jd;ik:  
jq;fsplkpUe;Jngwg;gLk; jfty;fs; ghJfhf;fg;gLtjw;fhd KO chpikAk; 
jq;fSf;Fcz;L. ,e;jgbtj;jpy; ifnahg;gkpLtJld; %yk;>jhq;fs; 
jq;fisgw;wpatptuq;fisAk;>Ma;Ttptuq;fisAk; Ma;thsh;>Ma;Telj;Jk; VidNahh; 
tiuKiwxOq;FFOtpdh; kw;Wk; rl;lj;jpw;Fcl;gl;lkUe;Jfl;Lg;ghL ,af;Feh; 
MfpNahh; ghh;itaplmDkjpf;fpNwd;. ,e;jMa;tpy; fhl;lg;gLk; jfty;fs; mwptpay; 
ehNsLfspNyhmwptpay; $l;lq;fspNyhrkh;g;gpf;fg;gLk; gl;rj;jpy; jq;fsJmilahsk; 
ntspg;gLj;jkhl;lhJ.  
Ma;tpd; eLtpy; mjpypUe;Jtpyfpf;nfhs;sepidj;jhy;:  
,e;jMa;tpy; gq;Nfw;gJjq;fspd; nrhe;jtpUg;gNkNkYk; Ma;tpd; eLtpy; 
ve;jNeuj;jpYk;>vf;fhuzKk; $whky; tpyfpf;nfhs;sjq;fSf;F KO chpikAk; cz;L. 
,Ug;gpDk; tpyFtjw;FKd; Ma;TFOTld; 
fye;JMNyhrpg;gJcfe;jJvdghpe;Jiuf;fg;gLfpd;wJ.  
Muha;r;rpahsh; ifnahg;gk; :             gq;Nfw;gthpd; ifnahg;gk; :    
Njjp :    Njjp:      
 
  
PATIENT CONSENT FORM 
Study Detail : “EVALUATION  OF A  SCORING  SYSTEM FOR PREDICTING  
THE RISK OF MALIGNANCY IN THYROID NODULES USING 
 CLINICAL, LABORATORY  AND SONOLOGICAL DATA” 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification 
Number 
:  
Patient may check (√) these boxes 
a) I confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask question and all my questions and 
doubts have been answered to my complete satisfaction. ❏ 
b) I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal 
rights being affected. ❏ 
c) I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities will 
not need my permission to look at my health records, both in respect of 
current study and any further research that may be conducted in relation 
to it, even if I withdraw from the study I agree to this access. However, I 
understand that my identity will not be revealed in any information 
released to third parties or published, unless as required under the law. I 
agree not to restrict the use of any data or results that arise from this 
study. ❏ 
d) I agree to take part in the above study and to comply with the instructions 
given during the study and faithfully cooperate with the study team and to 
immediately inform the study staff if I suffer from any deterioration in my 
health or well being or any unexpected or unusual symptoms. ❏ 
e) I hereby consent to participate in this study. ❏ 
f) I hereby give permission to undergo detailed clinical examination and 
blood investigations as required.  
 
 
Signature/thumb impressionSignature of Investigator 
 
 
Patient’s Name and Address:                 Study Investigator’s Name: 
 
Ma;tpd; xg;Gjy; 
 
Ma;tpd; jiyg;G:kUj;Jttptuq;fs;>Ez;zjph;tpy; ghpNrhjidtptuq;fs; kw;Wk; 
Ma;tfjfty;fisgad;gLj;jpijuha;Lfl;bapy; 
Vw;glf;$baGw;WNeha;f;fhdtha;igfzpf;fcjTk; 
xUkjpg;gPl;LKiwiagw;wpaMa;T.  
Ma;thshpd; ngah; : kU.r.rhjdh (mWitrpfpr;irMa;TgphpT)  
Ma;Tikak; : uh[Pt; fhe;jpmuRnghJkUj;Jtkid>nrd;id.  
__________________ vDk; ehd;>vdf;FnfhLj;Js;sjfty; 
jhisgbj;JGhpe;Jnfhz;Nld;. ehd; 
gjpndl;Ltaijfle;Js;sjhy;>vd;DilaRaepidTlDk;> KO Rje;jpuJlDk;> 
,e;jMuha;r;rpapy; vd;idNrh;j;Jf; nfhs;srk;kjpf;fpNwd;.  
  ehd; vdf;Fmspf;fg;gl;lXg;Gjy; gbtj;ijAk;>jfty;fisAk; 
gbj;JGhpe;Jnfhz;Nld;. Xg;Gjy; gbtj;jpy; cs;sjfty;fs; vdf;Ftpsf;fpf; 
$wg;gl;Ls;sd. Ma;tpd; jd;ikgw;wpvdf;Ftpsf;fg;gl;Ls;sJ. 
vd;DilachpikfisAk; nghWg;GfisAk; Muha;r;rpahsh; tpsf;fpf; $wpdhh;. 
ehd; ,JtiuvLj;Js;smidj;Jtpjkhdrpfpr;irKiwfisAk; Muha;r;rpahshplk; 
$wpAs;Nsd;. ,e;jMuha;r;rpapdhy; Vw;gLk; jPikfs; gw;wptpsf;fg;gl;ld.  
  ehd; Muha;r;rpahsUld; xj;Jiog;Ngd; 
vd;Wk;>vdf;FVw;glf;$bamrhjhuzkhdepfo;Tfs; gw;wpAk; 
cldbahfMuha;r;rpahshplk; njhptpg;Ngd; vd;WcWjp $WfpNwd;. 
,e;jMa;tpypUe;Jvg;NghJNtz;LkhdhYk; vf;fhuzKk; $whky; 
vd;idtpLtpj;Jf; nfhs;syhk; vd;gijmwpNtd;.  
  vd;dplk; ,Ue;Jngwg;gLk; jfty;fismuR>tiuKiwmjpfhhpfs; 
MfpNahh;fSld; gfph;e;Jnfhs;sMuha;r;rpahsh;fSf;FmDkjpmspf;fpNwd;. 
vd;Dilarpfpr;irf;fl;Lfisghh;itaplchpikcz;L. vd;Dilajfty;fspd; 
milahsk; ,ufrpakhfitf;fg;gLk; vd;gijmwpNtd;.  
 ,e;jMuha;r;rpapy; gq;Nfw;fjd;dpr;irahfKOkdJld; rk;kjpf;fpNwd;.  
 
gq;Nfw;gthpd; ifnahg;gk; / Nuif :  Ma;thshpd; ifnahg;gk;  
 
gq;Nfw;gthpd; ngah;  :    Ma;thshpd; ngah; : r.rhjdh 
,lk; :      ,lk; :  
Njjp :      Njjp :  
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